Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12

AUTHORS

Sarah E. Stump, Young E. Whang, Daniel J. Crona

ABSTRACT

Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient. Nine days following initiation of cabozantinib, the patient reported muscle cramps and serum CK had increased from levels 12 months earlier that were within normal limits to a grade 1 elevation of 244 units/L. Despite a dose reduction, her CK continued to rise over the next 2 months, leading to a peak CK of 914 units/L. Due to this grade 3 elevation, cabozantinib was permanently discontinued, and her CK subsequently returned to a grade 1 elevation within one week and then to baseline within 3 weeks. The temporal relationship between drug exposure and CK increase strongly suggests causality. To the authors' knowledge, this is the first reported case of CK elevation attributed to cabozantinib, but cabozantinib-induced CK elevations could be under-reported, and providers should monitor for musculoskeletal complaints during cabozantinib therapy. More... »

PAGES

1-4

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-018-0629-2

DOI

http://dx.doi.org/10.1007/s10637-018-0629-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105165749

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29956055


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Durham VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410332.7", 
          "name": [
            "Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stump", 
        "givenName": "Sarah E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA", 
            "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Whang", 
        "givenName": "Young E.", 
        "id": "sg:person.01006050445.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006050445.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina System", 
          "id": "https://www.grid.ac/institutes/grid.410711.2", 
          "name": [
            "Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA", 
            "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA", 
            "Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crona", 
        "givenName": "Daniel J.", 
        "id": "sg:person.0720003545.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720003545.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.leukres.2009.11.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000399221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-006-0701-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001355183", 
          "https://doi.org/10.1007/s10072-006-0701-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71222-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032250619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07435800500371706", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037814026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1981.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040267576", 
          "https://doi.org/10.1038/clpt.1981.154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc0708896", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043460231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000179893", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049991099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.11680", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050816493"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0204-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051212688", 
          "https://doi.org/10.1007/s12032-012-0204-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/thy.1998.8.1029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059318743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3949/ccjm.83a.14120", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079210426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.70.7398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083840373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrdp.2017.9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084129661", 
          "https://doi.org/10.1038/nrdp.2017.9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100164642"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient. Nine days following initiation of cabozantinib, the patient reported muscle cramps and serum CK had increased from levels 12\u00a0months earlier that were within normal limits to a grade 1 elevation of 244\u00a0units/L. Despite a dose reduction, her CK continued to rise over the next 2\u00a0months, leading to a peak CK of 914\u00a0units/L. Due to this grade 3 elevation, cabozantinib was permanently discontinued, and her CK subsequently returned to a grade 1 elevation within one week and then to baseline within 3\u00a0weeks. The temporal relationship between drug exposure and CK increase strongly suggests causality. To the authors' knowledge, this is the first reported case of CK elevation attributed to cabozantinib, but cabozantinib-induced CK elevations could be under-reported, and providers should monitor for musculoskeletal complaints during cabozantinib therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-018-0629-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints", 
    "pagination": "1-4", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "107f70effb713f64cb166db03b49433d49bc04bfa9f546f97f3b7c8535e6804c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29956055"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-018-0629-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105165749"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-018-0629-2", 
      "https://app.dimensions.ai/details/publication/pub.1105165749"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000609.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-018-0629-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0629-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0629-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0629-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0629-2'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-018-0629-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N4851379dbdd5400aa1d31768bbb3a84e
4 schema:citation sg:pub.10.1007/s10072-006-0701-0
5 sg:pub.10.1007/s12032-012-0204-1
6 sg:pub.10.1038/clpt.1981.154
7 sg:pub.10.1038/nrdp.2017.9
8 https://doi.org/10.1016/j.leukres.2009.11.002
9 https://doi.org/10.1016/s1470-2045(14)71222-7
10 https://doi.org/10.1016/s1470-2045(16)30107-3
11 https://doi.org/10.1056/nejmc0708896
12 https://doi.org/10.1080/07435800500371706
13 https://doi.org/10.1089/thy.1998.8.1029
14 https://doi.org/10.1159/000179893
15 https://doi.org/10.1200/jco.2016.70.7398
16 https://doi.org/10.3322/caac.21442
17 https://doi.org/10.3324/haematol.11680
18 https://doi.org/10.3949/ccjm.83a.14120
19 schema:datePublished 2018-12
20 schema:datePublishedReg 2018-12-01
21 schema:description Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient. Nine days following initiation of cabozantinib, the patient reported muscle cramps and serum CK had increased from levels 12 months earlier that were within normal limits to a grade 1 elevation of 244 units/L. Despite a dose reduction, her CK continued to rise over the next 2 months, leading to a peak CK of 914 units/L. Due to this grade 3 elevation, cabozantinib was permanently discontinued, and her CK subsequently returned to a grade 1 elevation within one week and then to baseline within 3 weeks. The temporal relationship between drug exposure and CK increase strongly suggests causality. To the authors' knowledge, this is the first reported case of CK elevation attributed to cabozantinib, but cabozantinib-induced CK elevations could be under-reported, and providers should monitor for musculoskeletal complaints during cabozantinib therapy.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf Nc04716b8a8934bb587403e62f6b67f7f
26 Ndb8ae686c23b4562a42f8df692e23ae4
27 sg:journal.1094201
28 schema:name Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
29 schema:pagination 1-4
30 schema:productId N7ddaf6d570a6435db0c2078f0e04a921
31 N8bb228de3db54c989d3b075f9479f3f5
32 Na8cf696b922e481a9f196006cb174575
33 Nd30ee75decec4dbc82ae4487b93fb3c3
34 Ne744f23ecee14530a95de9eb033c176a
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105165749
36 https://doi.org/10.1007/s10637-018-0629-2
37 schema:sdDatePublished 2019-04-10T16:05
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher N1203500d2aed43b6ba7924011fdae9ed
40 schema:url https://link.springer.com/10.1007%2Fs10637-018-0629-2
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N1203500d2aed43b6ba7924011fdae9ed schema:name Springer Nature - SN SciGraph project
45 rdf:type schema:Organization
46 N4851379dbdd5400aa1d31768bbb3a84e rdf:first N4a1e33c26c784f07acaa2b5a1e257b40
47 rdf:rest N4fca1b06ad6c4bfebedd1ac9ebac28b9
48 N4a1e33c26c784f07acaa2b5a1e257b40 schema:affiliation https://www.grid.ac/institutes/grid.410332.7
49 schema:familyName Stump
50 schema:givenName Sarah E.
51 rdf:type schema:Person
52 N4fca1b06ad6c4bfebedd1ac9ebac28b9 rdf:first sg:person.01006050445.56
53 rdf:rest Nf6f5f1a2ef4e4c5585d5a27e86eb8c06
54 N7ddaf6d570a6435db0c2078f0e04a921 schema:name pubmed_id
55 schema:value 29956055
56 rdf:type schema:PropertyValue
57 N8bb228de3db54c989d3b075f9479f3f5 schema:name doi
58 schema:value 10.1007/s10637-018-0629-2
59 rdf:type schema:PropertyValue
60 Na8cf696b922e481a9f196006cb174575 schema:name dimensions_id
61 schema:value pub.1105165749
62 rdf:type schema:PropertyValue
63 Nc04716b8a8934bb587403e62f6b67f7f schema:volumeNumber 36
64 rdf:type schema:PublicationVolume
65 Nd30ee75decec4dbc82ae4487b93fb3c3 schema:name readcube_id
66 schema:value 107f70effb713f64cb166db03b49433d49bc04bfa9f546f97f3b7c8535e6804c
67 rdf:type schema:PropertyValue
68 Ndb8ae686c23b4562a42f8df692e23ae4 schema:issueNumber 6
69 rdf:type schema:PublicationIssue
70 Ne744f23ecee14530a95de9eb033c176a schema:name nlm_unique_id
71 schema:value 8309330
72 rdf:type schema:PropertyValue
73 Nf6f5f1a2ef4e4c5585d5a27e86eb8c06 rdf:first sg:person.0720003545.45
74 rdf:rest rdf:nil
75 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
76 schema:name Medical and Health Sciences
77 rdf:type schema:DefinedTerm
78 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
79 schema:name Oncology and Carcinogenesis
80 rdf:type schema:DefinedTerm
81 sg:journal.1094201 schema:issn 0167-6997
82 1573-0646
83 schema:name Investigational New Drugs
84 rdf:type schema:Periodical
85 sg:person.01006050445.56 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
86 schema:familyName Whang
87 schema:givenName Young E.
88 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006050445.56
89 rdf:type schema:Person
90 sg:person.0720003545.45 schema:affiliation https://www.grid.ac/institutes/grid.410711.2
91 schema:familyName Crona
92 schema:givenName Daniel J.
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720003545.45
94 rdf:type schema:Person
95 sg:pub.10.1007/s10072-006-0701-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001355183
96 https://doi.org/10.1007/s10072-006-0701-0
97 rdf:type schema:CreativeWork
98 sg:pub.10.1007/s12032-012-0204-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051212688
99 https://doi.org/10.1007/s12032-012-0204-1
100 rdf:type schema:CreativeWork
101 sg:pub.10.1038/clpt.1981.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040267576
102 https://doi.org/10.1038/clpt.1981.154
103 rdf:type schema:CreativeWork
104 sg:pub.10.1038/nrdp.2017.9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084129661
105 https://doi.org/10.1038/nrdp.2017.9
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1016/j.leukres.2009.11.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000399221
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1016/s1470-2045(14)71222-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032250619
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1056/nejmc0708896 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043460231
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1080/07435800500371706 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037814026
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1089/thy.1998.8.1029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059318743
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1159/000179893 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049991099
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1200/jco.2016.70.7398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083840373
122 rdf:type schema:CreativeWork
123 https://doi.org/10.3322/caac.21442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100164642
124 rdf:type schema:CreativeWork
125 https://doi.org/10.3324/haematol.11680 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050816493
126 rdf:type schema:CreativeWork
127 https://doi.org/10.3949/ccjm.83a.14120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079210426
128 rdf:type schema:CreativeWork
129 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
130 schema:name Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
131 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
132 rdf:type schema:Organization
133 https://www.grid.ac/institutes/grid.410332.7 schema:alternateName Durham VA Medical Center
134 schema:name Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
135 rdf:type schema:Organization
136 https://www.grid.ac/institutes/grid.410711.2 schema:alternateName University of North Carolina System
137 schema:name Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
138 Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, 27599, Chapel Hill, NC, USA
139 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...